SRPT Sarepta Therapeutics Inc.

124.16
-3.18  -3%
Previous Close 127.34
Open 128.55
Price To Book 6.83
Market Cap 9,206,944,251
Shares 74,153,868
Volume 1,011,001
Short Ratio
Av. Daily Volume 971,265

NewsSee all news

  1. This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data
  2. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  3. The Sarepta Therapeutics (NASDAQ:SRPT) Share Price Is Up 612% And Shareholders Are Delighted
  4. Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray
  5. Here’s What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due mid-2019.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 dosing to be completed 2Q 2019.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Phase 1 trial safety and dosing insight due by end of 2019 or 1Q 2020.
SRP-5051 - PPMO
Duchenne muscular dystrophy
PDUFA date under priority review August 19, 2019 .
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 data February 27, 2019 noted mean of 51% beta-sarcoglycan positive fibers.
MYO-101
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)

Latest News

  1. This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data
  2. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  3. The Sarepta Therapeutics (NASDAQ:SRPT) Share Price Is Up 612% And Shareholders Are Delighted
  4. Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray
  5. Here’s What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)
  6. Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
  7. Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue?
  8. Vertex Expands Collaboration With CRISPR, Acquires Exonics
  9. Vertex enters Duchenne field with $245M buy of Exonics
  10. Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  11. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  12. Market Weekly Review: Lower Prices Create Buying Opportunities
  13. Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT
  14. This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
  15. Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript
  16. Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
  17. When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?